Plus Therapeutics
PSTV
PSTV was delisted on the 31st of July, 2026.
23 hedge funds and large institutions have $1.49M invested in Plus Therapeutics in 2026 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 8 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
0.12% less ownership
Funds ownership: 0.34% → 0.21% (-0.12%)
8% less funds holding
Funds holding: 25 → 23 (-2)
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
75% less capital invested
Capital invested by funds: $5.92M → $1.49M (-$4.43M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$186K |
| 2 |
Millennium Management
New York
|
+$82.4K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$26.4K |
| 4 |
Mercer Global Advisors
Denver,
Colorado
|
+$19.4K |
| 5 |
MFS
Miller Financial Services
Marshall,
Michigan
|
+$15.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
L1 Global Manager
Melbourne,
|
-$1.17M |
| 2 |
Jane Street
New York
|
-$525K |
| 3 |
VF
Virtu Financial
New York
|
-$254K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$239K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$94.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VF
26
Virtu Financial
New York
| – | -$254K | -19,870 | Closed |
|
|
27
Citadel Advisors
Miami,
Florida
| – | -$94.8K | -7,402 | Closed |
|
28
HighTower Advisors
Chicago,
Illinois
| – | -$8.2K | -640 | Closed |
|
|
JWCA
29
J.W. Cole Advisors
Tampa,
Florida
| – | -$5.12K | -400 | Closed |
|
30
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$1K | -56 | Closed |
|
31
Bank of America
Charlotte,
North Carolina
| – | -$648 | -51 | Closed |
|
PSTV Hedge Fund Activity: Q1 2026 in Review
23 of the 8,137 institutional investors tracked by Wall St. Rank reported a position in Plus Therapeutics (PSTV) for Q1 2026, worth a combined $1.49M — down 75% from $5.92M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of PSTV and 7 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 5 added.
The largest buyer was Geode Capital Management, adding an estimated $186K. The largest seller was L1 Global Manager, exiting entirely with an estimated $1.17M sold.
- 23 institutional investors held Plus Therapeutics (PSTV) as of Q1 2026, down from 25 in Q4 2025.
- Funds reported $1.49M of Plus Therapeutics stock for Q1 2026, down 75% quarter-over-quarter.
- 7 funds opened new Plus Therapeutics positions in Q1 2026 and 8 closed out, a net change of -1 holder.
- The largest Plus Therapeutics buyer in Q1 2026 was Geode Capital Management, an estimated $186K added.
- The largest Plus Therapeutics seller in Q1 2026 was L1 Global Manager, an estimated $1.17M sold.
Based on aggregated 13F filings for Q1 2026.